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Abstract Structured follow-up after revascularisation for chronic critical limb ischaemia
(CLI) aims at sustained treatment success and continued best patient care. Thereby,
efforts need to address three fundamental domains: (A) best medical therapy, both
to protect the arterial reconstruction locally and to reduce atherosclerotic burden
systemically; (B) surveillance of the arterial reconstruction; and (C) timely initiation of
repeat interventions. As most CLI patients are elderly and frail, sustained resolution of
CLI and preserved ambulatory capacity may decide over independent living and overall
prognosis. Despite this importance, previous guidelines have largely ignored follow-up after
CLI; arguably because of a striking lack of evidence and because of a widespread assumption
that, in the context of CLI, efﬁcacy of initial revascularisation will determine prognosis
during the short remaining life expectancy. This chapter of the current CLI guidelines
aims to challenge this disposition and to recommend evidentially best clinical practice by
critically appraising available evidence in all of the above domains, including antiplatelet
and antithrombotic therapy, clinical surveillance, use of duplex ultrasound, and indications
for and preferred type of repeat interventions for failing and failed reconstructions.
However, as corresponding studies are rarely performed among CLI patients speciﬁcally,
evidence has to be consulted that derives from expanded patient populations. Therefore,
most recommendations are based on extrapolations or subgroup analyses, which leads to an
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almost systematic degradation of their strength. Endovascular reconstruction and surgical
bypass are considered separately, as are speciﬁc contexts such as diabetes or renal failure;
and critical issues are highlighted throughout to inform future studies.
© 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
1. Introduction
Follow-up after revascularisation for chronic critical limb
ischaemia (CLI) should ensure not only best clinical results
including survival, limb salvage and resolution of chronic
CLI with sustained functional improvement and improved
quality of life, but also timely amputation in case of
failure and improved cost-efﬁciency by structured outcome
analysis.1 Appropriate endpoints for assessment of these
goals, however, are still used inconsistently, which handicaps
comparisons.2
Follow-up after revascularisation needs to address three
main issues: (A) best medical therapy, (B) surveillance
of arterial reconstruction and (C) indication of repeat
revascularisation or timely amputation. As patients with CLI
are usually elderly and frail, preserved ambulatory capacity
will often decide over independent living, but efforts at
limb salvage need to be balanced realistically against the
likelihood of continued independence. An associated chal-
lenge is the implementation of structured follow-up, which is
difﬁcult to achieve even in solid studies with rigorous record-
keeping.3 Most studies are retrospective and use inconsistent
reporting standards, and only a few are stratiﬁed for
presence of CLI. This explains why high-level evidence
is scarce, particularly for follow-up after endovascular
reconstruction;2 and why follow-up after revascularisation
for CLI has largely been ignored in previous guidelines.4,5
Critical issue
There is a need for well-designed clinical studies
evaluating follow-up strategies and indications for speciﬁc
prognostic, diagnostic or therapeutic interventions during
follow-up after revascularisation for CLI.
2. Best medical care
Best medical treatment and smoking cessation advice are
considered a mainstay of care for all vascular patients, even
though this has not been explored speciﬁcally in the context
of CLI. Monitoring of patient compliance is of paramount
importance and an effective way to involve primary care
providers into a general therapeutic concept.
2.1. Best medical treatment and cardiovascular risk
reduction
The evidence for best medical treatment and systemic
cardiovascular risk reduction is addressed in Chapter III
(Management of Cardiovascular Risk Factors and Medical
Therapy, pp. S33––S42) and should be applied independently
of the type of local revascularisation that has been
achieved.
A post hoc analysis of the PREVENT III cohort6 investigated
the efﬁcacy of statins, beta blockers and antiplatelet agents
during follow-up in 1404 patients with CLI undergoing venous
bypass grafting. Use of statins was independently associated
with a statistically signiﬁcant survival advantage at 1 year
(HR 0.67; 95%CI 0.51––0.90; p = 0.001), but none of the
drug classes taken separately was associated with a better
graft patency in this study. In contrast, daily use of statins
in addition to acetylsalicylic acid (ASA) almost halved rates
of both restenosis (42% vs. 22%) and lower limb amputation
(21% vs. 11%) at 1 year after percutaneous transluminal
angioplasty in patients with severe claudication or CLI.7
A similar favourable effect of statins on graft patency
(OR 3.7; 95%CI 2.1––6.4) and amputation rate (OR 0.34;
95%CI 0.15––0.77) has also been observed at 1.5 years after
venous bypass grafting (70% CLI patients) in other studies.8,9
2.2. Platelet inhibition and antithrombotic therapy
Venous grafts used as arterial bypass suffer the loss of their
endothelial layer within days after implantation,10 which
triggers increased expression and exposure of tissue factor
within the vein graft. The ensuing thrombogenic process is
led primarily by the activated coagulation system, although
activated platelets may also play a role.11 In contrast,
introduction of a prosthetic surface such as polyethylene
terephthalate (PET), PTFE or endovascular stents initiates a
thrombogenic process that is led predominantly by activated
platelets.
This may explain consistent observations of a differential
efﬁcacy of antiplatelet vs. antithrombotic agents regarding
prevention of thrombotic occlusion of vascular reconstruc-
tions,11––13 although none of these Cochrane meta-analyses
was stratiﬁed for CLI. However, reconstructions for CLI can
be assumed particularly prone to thrombotic occlusion due
to low ﬂow, suggesting that ﬁndings as shown in Table 1
remain pertinent to patients with reconstructed CLI.
2.2.1. Surgical reconstruction
After lower limb bypass, antiplatelet treatment (i.e. ASA
alone or in combination with dipyridamole) improves primary
patency at 1-year follow-up.12 However, the size of this
effect differs when patients with prosthetic and venous
grafts are considered separately. In patients with PTFE
or PET bypass, antiplatelet drugs are more efﬁcient and
improve primary patency as early as 1 month after surgery
with a durable effect thereafter. In contrast, patients
with venous bypass beneﬁt less from platelet inhibition
and the effect becomes statistically signiﬁcant only at
1-year follow-up.12 Ticlopidine, another antiplatelet agent,
may be more effective. In a multicentre RCT comparing
ticlopidine vs. placebo, ticlopidine signiﬁcantly improved
primary venous graft patency rates at 6, 12 and 24 months
but not at 3 months.14
In contrast, vitamin K antagonists (VKA) have a strong
but time-limited protective effect occurring early on venous
graft patency at 3 and 6 months, but disappearing at 1, 2
and 5 years.11 Attempts to improve venous graft patency
with heparin have produced conﬂicting results: although
daily administration of 2500 international units (IU) of low-
molecular-weight heparin (LMWH) for 3 months after bypass
surgery did not confer any beneﬁt as compared to 300mg ASA
across a single-institution RCT, stratiﬁed analysis of the
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subset of CLI patients suggested markedly improved patency
rates at 6 and 12 months.15 However, addition of LMWH to
ASA failed to improve primary graft patency in a RCT of 284
CLI patients.16
In a comparison of VKA and ASA alone or in combination
with dipyridamole, VKA was superior in 1637 patients with
venous grafts, whereas antiplatelet agents had a stronger
effect on 1104 prosthetic grafts at 2 years.11
Finally, the multicentre CASPAR trial17 randomly assigned
851 patients receiving below-the-knee bypass surgery to
ASA alone or to ASA plus thienopyridine (clopidogrel).
Endpoints of the study were bypass patency, absence of
restenosis, major amputation or death. No difference was
observed in this trial among the two groups, but a subgroup
analysis suggested a beneﬁt of dual antiplatelet therapy for
patients receiving prosthetic grafts (HR 0.65; 95%CI 0.45––
0.95; p = 0.025). This was achieved without a signiﬁcant
increase of the risk of major bleeding.
The therapeutic range of vitamin K antagonism needs
consideration as improved anticoagulation control seems
to halve the risk of adverse events.18 In a general
population, the optimum risk––beneﬁt range lies between
an international normalised ratio (INR) of 2 and 3,19 with
moderately higher INR still safe. For peripheral artery bypass
surgery, patients spending most time during follow-up in an
INR range between 3 and 4 had fewest thrombo-embolic or
haemorrhagic events in a post hoc analysis of the Dutch BOA
trial cohort.20
To summarise the current literature, it appears that
platelet inhibitors improve graft patency rates as compared
to placebo. Patients with a prosthetic graft are likely to
beneﬁt more from platelet inhibitors than those with a
venous graft. On the other hand, patients with a venous
bypass appear to beneﬁt more from vitamin K antagonists
than platelet inhibitors, particularly following below-the-
knee bypass. But these results should be interpreted with
caution due to the heterogeneity of the studies including
different proportions of patients with CLI and several types
of reconstructions.
2.2.2. Endovascular reconstruction
Administration of ASA combined with dipyridamole appears
to reduce the incidence of restenosis or occlusion after
superﬁcial femoral artery (SFA) endovascular intervention by
60% at 1 year.13 However, this result could be confounded
by a high proportion of claudicants as platelet inhibitors
might be less effective in patients with CLI. A meta-analysis
of four trials comparing high-dose (300––1000mg) to low-
dose (50––300mg) ASA regimens indicated that higher doses
did not signiﬁcantly improve patency rates but increased
gastrointestinal side effects.13
Although platelet inhibitors seem generally superior to
VKA, single pathway inhibition may be insufﬁcient to protect
extensive endovascular reconstructions.13,21 According to
a small single-centre RCT, GPIIb/IIIa inhibitors such as
abciximab are promising to prevent early thrombotic
occlusions in high-risk situations.21 However, abciximab has
to be administered intravenously and its long-term effects
are unclear.
Another single-centre RCT involved 275 patients under-
going peripheral artery angioplasty to compare the effect
of 2500 IU of LMWH in addition to ASA vs. ASA alone for
3 months. Although no effect was observed across the trial,
a subgroup analysis of patients with CLI showed a risk
reduction from 72% to 45%.22
To summarise these ﬁndings, there is no high-level
evidence regarding the optimum antithrombotic strategy
after endovascular interventions for CLI (Table 1). Long-
term platelet inhibitors (50––300mg ASA) appear to be
the preferred drug therapy compared to vitamin K
antagonists. Platelet inhibitors should be given prior to
intervention. Evidence from coronary interventions suggests
that more potent platelet inhibitors such as thienopyridines
(clopidogrel) or dual antiplatelet therapy might confer
additional beneﬁts; however, speciﬁc data for CLI are
lacking. Finally, time-limited subcutaneous administration
of LMWH may improve primary patency following peripheral
artery angioplasty.
2.3. Exercise training
There is conclusive evidence that exercise training is
beneﬁcial for patients suffering from claudication,23 par-
ticularly if supervised.24 However, no study has addressed
the potential value of supervised exercise training in
CLI patients recovering from revascularisation. One reason
may be that these frail patients often present with co-
existent morbidity, which may compromise compliance with
a structured exercise programme or make it impractical.
Nonetheless, exercise training may be assumed beneﬁcial
in CLI patients who become asymptomatic or with a mild
claudication remaining after arterial revascularisation.
Recommendations
Following vein bypass surgery for CLI, ASA or ASA combined
with dipyridamole, is efﬁcient in lowering the incidence
of thrombotic occlusions (Level 1b; Grade B); however,
vitamin K antagonists are superior when closely monitored
and should be preferred in suitable patients during
early follow-up, particularly for below-the-knee bypass.
(Level 1b; Grade B)
Ticlopidine is efﬁcient in protecting vein bypass from
occlusion (Level 1b; Grade B) and may be used as an
alternative to vitamin K antagonists. (Level 3; Grade D)
Daily administration of 2500 IU of low molecular weight
heparin during 3 months after venous bypass may be
beneﬁcial (Level 2b; Grade C) and is superior to
unfractionated heparin. (Level 1b; Grade B)
After prosthetic bypass or endovascular revascularisation,
ASA, or ASA combined with dipyridamole, should be given
daily at low dose (50 to 300mg) to lower the incidence
of bypass or angioplasty occlusions (Level 1b; Grade B).
Additional use of thienopyridine (clopidogrel) may be
beneﬁcial without increasing the risk of major bleeding.
(Level 2b; Grade C)
In general, vitamin K antagonists do not seem efﬁcient for
prosthetic bypasses (Level 1b; Grade B); however, they
may be considered additionally to platelet inhibitors for
low-ﬂow (<45 cm/s) prosthetic grafts. (Level 4; Grade C)
Vitamin K antagonists should be closely monitored to lower
the risk of adverse events (Level 2b; Grade B). An INR
between 2 and 4 is efﬁcient for patients receiving surgical
bypass, but values between 3 and 4 seem most efﬁcient
and are probably safe. (Level 2b; Grade C)
continued on next page
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Recommendations (cont’d)
Continued use of statins is associated with improved
patency rates and limb salvage after venous bypass and
endovascular reconstruction. (Level 2b; Grade C)
Whenever possible, patients with CLI should be motivated
to undergo supervised exercise training following a
successful revascularisation. (Level 5; Grade D)
Critical issues
• Several studies have suggested an adverse effect of
increased homocysteine serum levels on progression of
atherosclerosis.25,26 Homocysteinaemia-lowering therapy
is theoretically available; however, its clinical value is still
unknown25 and should be addressed in RCTs.
• Similarly, the value of (supervised) exercise training after
revascularisation of CLI should be established.
• In current practice, many vascular centres give platelet
inhibitors to patients with a venous bypass, although,
regarding graft patency, available evidence favours VKA.11
Probable reasons are concerns regarding compliance of
these elderly patients and anticipated difﬁculties to
ensure safe VKA levels. Besides, local beneﬁts may be
considered less important than systemic protective effects
of platelet inhibitors, which are detailed in Chapter III.
Therefore, it would be interesting to compare a dual
antiplatelet regimen to VKA in CLI patients. On any
account, optimum duration of VKA after venous bypass
needs to be established as protective early effects may
be time-limited.
• Similarly, the role of clopidogrel, or clopidogrel in
combination with ASA, needs to be evaluated in prosthetic
grafts and endovascular reconstructions as does the
optimal therapeutic range of VKA and its duration.
• New antithrombotic agents including direct thrombin in-
hibitors, mega-pentasaccharides, tissue factor/factor VIIa
complex inhibitors and oral factor Xa inhibitors might be
promising perspectives and should be properly evaluated.
Particularly factor Xa inhibitors may be safer and easier
to use than vitamin K antagonists, but approval for use
outside prevention of thromboembolism is pending.
• For CLI patients, RCTs should not only concentrate on
primary patency rates but also integrate other clinically
meaningful endpoints such as limb salvage, resolution of
CLI and survival.2
3. Surveillance
The goal of arterial reconstructions is to improve arterial
blood ﬂow. Therefore, surveillance of sustained treatment
success usually concentrates on monitoring patency (Ta-
ble 2). However, sustained patency may not always be
needed to achieve limb salvage or to obtain resolution of
CLI.29,36 Conversely, around 10% of patent reconstructions
eventually fail despite improved macro-circulation.37––39 Pre-
operative factors such as independency and mental capacity
may be important independent predictors of functional
recovery.39––41 Therefore, primary patency alone may not be
the ideal surrogate measure for treatment success,29 and
other efﬁcacy measures should also be considered.2
Prospective analyses suggest that the quality of life of
CLI patients depends directly on sustained patency of the
reconstruction.42 As revisions for failing grafts are far more
successful than revisions for failed grafts and generate less
cost,43––45 surveillance programmes have been recommended
to detect failing grafts and to prevent graft occlusion.27
But no study has ever examined the value of surveillance
programmes as such by comparing surveillance to no
surveillance (Table 2). There is also a controversy regarding
the best and most cost-effective surveillance method.46
Regular clinical revaluations including interval patient
history, clinical examination and non-invasive assessment
of perfusion using ankle-brachial pressure index (ABI) are
generally accepted. The controversy exists on whether
additional routine screening by duplex ultrasound confers
any clinical beneﬁt (Table 2).1
3.1. Surveillance of surgical reconstruction
3.1.1. Autologous vein bypass
Venous grafts are prone to stenoses during follow-up
precipitating reduced blood ﬂow and graft failure.47 Most
stenoses occur within the ﬁrst year, and about 25––30% of
vein grafts are affected.44 Nature of failure varies according
to its timing.29 Failure within 30 days is usually attributed to
a technical surgical error, whereas failure between 30 days
and 1 year is usually due to developing stenosis. Both
are obvious targets of surveillance efforts. In contrast,
late failure often follows progression of the disease and is
conceptually addressed by best medical care.
Duplex ultrasound scanning is the preferred non-invasive
method for detecting stenotic lesions (see Chapter II,
Diagnostic Methods, pp. S13––S32). A systematic review
of 6649 vein grafts concluded that colour duplex (CD)
surveillance signiﬁcantly reduced the total number of
occluded grafts as well as the incidence of graft occlusions
after 30 days;27,33 However, overall limb salvage was not
improved by CD screening.27
Although there is no RCT exploring the potential beneﬁt
of CD surveillance speciﬁcally among CLI patients, four RCTs
have investigated CD in a large population receiving surgical
bypass.1 Three RCTs concentrated on venous bypass,3,28,29
and one RCT also included prosthetic grafts.31 The latter
randomly assigned 156 patients to either CD screening every
3 months for 2 years or to clinical surveillance including
ABI measurements at yearly intervals. At 3 years, assisted
primary and secondary patency rates were signiﬁcantly
improved by CD screening (78% vs. 53% and 82% vs. 56%,
respectively; p < 0.05); however, amputation rates were
not affected.31 In contrast, no difference was found in
another trial between CD and ABI measurements at 3-month
intervals regarding patency and limb salvage at 1 year even
though more grafts had been revised under CD screening.28
This ﬁnding was essentially conﬁrmed by the largest RCT29
that involved 594 patients receiving vein bypass and
demonstrated that CD surveillance failed to confer a clinical
beneﬁt in terms of limb salvage or quality of life, but
incurred additional costs.
None of these trials was stratiﬁed for CLI. Moreover, only
patients with a patent graft at 4––6 weeks after surgery were
randomised. However, a likely key beneﬁt of CD is the early
identiﬁcation of silent lesions; therefore exclusion of the
patients with early graft abnormalities may have missed one
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important advantage of CD. Thus, despite lacking Level 1
evidence, CD screening has a role and should probably be
focused on patients with a high risk of graft failure and be
initiated immediately after revascularisation.44,48
3.1.2. Duplex screening for failing revascularisations
A signiﬁcant proportion of patients (around 25%) has an
abnormal early CD1,29,49 (i.e. peak systolic velocity of less
than 45 cm/s; peak systolic velocity increase to more than
150 to 300 cm/s; or velocity ratio across a suspected stenosis
of more than 2.0 to 3.5). This might be occurring despite
a normal intraoperative completion angiogram. Half of
these patients will eventually need repeat interventions,8,50
whereas the other half will see these abnormalities on CD
remaining stable or even regressing.49
Thus, an abnormal initial CD could, together with other
risk factors, help to identify patients at a high risk of graft
failure who might beneﬁt from continued CD screening.51––53
The most important additional predictors include falling
serial ABI (by more than 0.1 to 0.2), composite or small
diameter (<3mm) vein bypass, redo-bypass grafts, long
grafts (>50 cm in length) and alternative autologous venous
conduits (i.e. arm or small saphenous veins).54 Interestingly,
absolute ABI was not predictive of failure in a post hoc
analysis of a large multicentre RCT.51
In contrast, patients with normal CD scans at 6 weeks to
6 months had a very low risk for subsequent graft occlusion if
clinical surveillance remained normal.30,55 Others found that
the incidence of graft stenosis does not decline signiﬁcantly
during the ﬁrst year.56 Therefore, selective CD surveillance
for less than 1 year could miss about 30% of lesions
eventually leading to revision.
3.1.3. Prosthetic bypass grafts
Although evidence regarding efﬁcacy of CD surveillance for
prosthetic bypass is weak,1 consistent estimates indicate
that occlusions of prosthetic grafts are rarely preceded
by a detectable stenosis (Table 2). Thus, even intensive
surveillance programmes failed to detect salvageable lesions
prior to occlusion in a large percentage of prosthetic grafts.8
If anything, low ﬂow (<45 cm/s midgraft velocity) rather
than high ﬂow seems a more common mode of presentation,
and early CD may be useful to identify these prosthetic
grafts at increased risk, which might beneﬁt from combined
antiplatelet and anticoagulant therapy.34 However, in one
RCT that involved prosthetic bypass grafts, no beneﬁt was
shown for CD surveillance during 1 year.31
3.1.4. Cost
The mean cost for 5-year surveillance including CD has been
estimated to be that of the initial bypass graft procedure,
whereas the cost of bypass procedure plus surveillance for
5 years approaches the total cost of primary amputation.43
But revision of a stenotic but patent bypass identiﬁed by CD
is signiﬁcantly less expensive than revision for graft occlusion
which is also followed signiﬁcantly more often by a major
amputation (33% vs. 2%). Therefore, limb salvage-related
expenses57 appear to be justiﬁed in CLI patients.58 In
fact, CD needs to prevent only 5% of patients from an
amputation to be economically viable.29 On the other hand,
repeated unsuccessful attempts to revascularise a leg will
disproportionally increase the cost without any proﬁt for the
patient.58
3.2. Surveillance of endovascular reconstruction
A fundamental difference of surveillance for endovascular
interventions comes from the obvious challenge to localise
the treated arterial segment precisely and not to confound
restenosis or re-occlusion with progressive arterial disease
elsewhere on the same artery. This is reﬂected by
the distinction between target lesion re-intervention and
target extremity re-intervention as important endovascular
outcomes.2 The preservation of collateral vessels during
endovascular recanalisation may attenuate the clinical
impact of restenosis or reocclusion. Therefore CD could be
of less value in an endovascular context. So far, no RCT
has investigated the use of routine CD after endovascular
interventions. However, by extrapolation, close post-
interventional follow-up and timely repeat interventions
are generally accepted,59,60 but the same result could
probably be achieved by clinical surveillance alone with
similar effectiveness. As with surgical bypass, selective
early CD screening may be beneﬁcial after interventions as
early duplex is able to detect a residual stenosis missed
on completion angiography in up to half of patients. Such
stenosis is known to be associated with a higher amputation
rate when compared to normal early CD (20% vs. 5%).35
3.2.1. Expected ulcer healing
It is important to note that, even after successful
revascularisation, ischaemic tissue lesions may heal only
slowly. Important therapeutic adjuncts include appropriate
removal of ischaemic tissue, dedicated wound management
including ultrasound and negative-pressure wound therapy,
targeted antibiotic therapy of infections with abscess, and
any measure to improve immune-deﬁcient states of any
origin. These measures are dealt with in great detail in
Chapter V (Diabetic Foot, pp. S60––S74) of these guidelines.
Expected median time to complete healing is in the range
of 190 days.61,62 Diabetes and insufﬁcient diabetes control
are the most important predictors of delayed healing; these
are dealt with in Chapters III and V. Female gender is a
risk factor for wound complications after bypass surgery
in patients with CLI.63 However at 1 year, 75% of ulcers
can be expected to have healed.61,62 Lesions at mid- or
hindfoot level are the most critical to heal, whereas duration
of ulceration before revascularisation is not predictive of
healing time. Foot care, mechanical unloading and stump
healing (for prosthetic accommodation of amputation) are
critical to retain tissue integrity and ambulatory capacity,
and are detailed in Chapter V.
Recommendations
An early (30 day) colour duplex scan should be done
for venous bypass grafts in CLI patients. However, best
level evidence does not support the use of routine long-
term colour duplex surveillance for venous bypass grafts
that are undisturbed at 1 month (Level 1b; Grade B).
Instead, 3- to 6-monthly clinical review with ankle-
brachial pressure index measurements should be utilised
for at least 2 years. (Level 2a; Grade B)
Clinical deterioration and a drop in ankle-brachial
pressure index of 0.1––0.2 indicate a failing infrainguinal
vein bypass and should trigger focused colour duplex
examination. (Level 1b; Grade B)
continued on next page
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Recommendations (cont’d)
A colour duplex scan at 6 weeks to 6 months helps
predicting which venous graft is likely to fail and should
beneﬁt from surveillance. (Level 2b; Grade C)
Other reconstructions with a likely beneﬁt from colour
duplex surveillance include composite vein bypass, redo-
bypass grafts, small diameter (<3mm) venous grafts, long
vein bypass (>50 cm) and alternative autologous venous
conduits. (Level 2b; Grade C)
An early colour duplex scan is useful after endovascular
revascularisation for CLI to identify those at risk for
failure (Level 3b; Grade C). However, there is no evidence
supporting routine long-term colour duplex surveillance
after endovascular revascularisation.
Best level evidence does not support the use of colour
duplex imaging compared to clinical follow-up with ankle-
brachial pressure index measurements every 3 months in
patients with prosthetic bypass. (Level 1b; Grade B)
Critical issues
• More studies are needed to ensure general applicability
of the above ﬁndings to patients with CLI, including the
preferred duration of CD and/or clinical surveillance.
• The role and duration of CD surveillance after endovas-
cular revascularisation including use of stents, subintimal
recanalisation and endarterectomy devices should be
better evaluated as compared to clinical surveillance with
ABI measurements.
• Cost-effectiveness analyses are lacking regarding pre-
ferred surveillance modalities after bypass or endovascu-
lar revascularisation in patients with CLI.
• There is a need for stratiﬁed analyses comparing pro-
phylactic measures, surveillance or repeat interventions
during follow-up between above- and below-the-knee
bypass in CLI patients. Available evidence pertains
predominantly to below-the-knee reconstructions, but
differential outcomes should be explored.
4. Repeat revascularisation
Approximately 40% of CLI patients undergoing vein bypass
will need a secondary intervention during follow-up; and in
a third of them the contralateral limb will be involved.52,64
Around 20% of bypass procedures result in graft occlusion
or amputation.53,54,65,66 Overall, this rate corresponds to an
estimated average of 1.75 repeat interventions per patient
for a 3-year period.64
The success rate of secondary procedures for endovascular
and surgical techniques is generally high, as long as the
bypass or the angioplasty segment is not occluded. In
contrast, once a graft has failed long-term patency is poorer
after revision and limb salvage rate is moderate.67 Timing
of bypass failure is an important indicator of prognosis:
the risk of amputation increases ﬁve-fold for early bypass
failure (<30 days) as compared to failure after 30 days, as
half of patients with early failure will develop untreatable
critical ischaemia and immediate amputation.65 Similarly,
early repeat intervention (<120––180 days) is associated with
impaired outcome as compared to late re-intervention.68,69
4.1. Failing bypass
Stenotic vein bypass can be salvaged with similar success
by endovascular or surgical techniques,54,59,68,70 even though
surgical revisions are more durable and necessitate fewer
subsequent re-interventions.71 Midgraft stenoses are more
benign than anastomotic stenoses,70 and late-appearing
short lesions have a favourable prognosis as compared to
early and extensive stenoses.68 Overall revision failure is
in the range of 30% and is similar between surgical and
endovascular approaches.71
For stenoses located within the main body of the graft,
surgical patch angioplasty and interposition grafting using
autologous vein are equally effective in prolonging assisted
primary patency. Alternatively, endovascular angioplasty
may be used with comparable early results,71,72 although
results are not as good as primary endovascular interventions
for native CLI lesion.73 Thus, the choice of the technique
depends on anatomical characteristics and accessibility of
the lesion.47
Outcome of recurrent stenosis is markedly inferior
with endovascular angioplasty, and such lesions probably
beneﬁt from surgical revision.74 Other types of lesions
for which surgical repair should be preferred based on
its durability include early lesions and lesions within
anastomoses.70 Endovascular revision is probably best suited
for short (<2 cm) and late-appearing lesions (>3––4 months)
involving the mid-graft, where it reaches similar durability
as surgical revision.58,68––70
4.2. Failed bypass
Bypass occlusion is a critical event and should undergo
urgent revision if the bypass is to be maintained. However,
graft salvage attempts fail in up to 65% of patients;57,65
and about half of graft occlusions will eventually lead to
amputation.34,65
For occluded vein grafts, surgical revision including
placement of a new bypass is preferred, since endovascular
revision is less durable.71 For occluded prosthetic bypasses,
graft salvage surgery is associated with acceptable long-term
results only for above-the-knee or extra-anatomic grafts.
Occluded below-the-knee grafts are preferably replaced by
a new bypass to a new outﬂow artery using an autologous
vein.66
In some cases, catheter-directed thrombolysis is an
appealing alternative. In a recent RCT, a mixed cohort of
124 patients with bypass occlusion was assigned to either
surgical revision or intra-arterial thrombolysis.75 Catheter
placement failed in almost 40% of cases and composite
clinical outcome at both 30 days and 1 year favoured
surgical revision with new graft placement for chronically
(>14 days) occluded grafts. However, patients with acute
graft thrombosis (<14 days) had a lower amputation rate
after successful thrombolysis at 1 year. Other authors
have conﬁrmed intra-arterial thrombolysis as a favourable
strategy for acute graft occlusions and that it seems to
give best results in above-the-knee prosthetic grafts in place
at least for 1 year.76 However, half of these grafts re-occlude
within 1 month, particularly if thrombolysis fails to unmask
an underlying correctable stenosis.76,77
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4.2.1. Endovascular reconstruction
In 35% of cases a repeat intervention is needed within 1 year
after endovascular revascularisation for CLI.59,60 Although
technical success of second-time endovascular angioplasty is
in the range of 95%, its mid-term patency may be limited,69
particularly in diabetic patients.59 Therefore, multiple re-
interventions may be needed for sustained limb salvage.59
Early failure (<180 days) of initial endovascular intervention
is a predictor of poor success of secondary intervention69 and
indicates that surgical alternatives should be considered.
Overall, similar proportions of failed endovascular recon-
structions are amenable to surgical or endovascular revision
with comparable results.59,60 Therefore, attempts at revision
should be tailored individually.
Recommendations
In venous bypass, an early (<4 months) stenosis or one
that involves the anastomosis may beneﬁt from surgical
revision (Level 2b; Grade C). In this setting, patch
angioplasty using autologous vein and interposition vein
grafts are equally effective. (Level 2b; Grade B)
Late-appearing and short (<2 cm) stenosis located within
the main body of a vein graft can be treated with
equivalent efﬁcacy using endovascular intervention or
surgical revision (Level 2b; Grade B). However, recurrent
stenosis has an inferior outcome when treated by
angioplasty and is likely to beneﬁt from surgical revision.
(Level 4; Grade C)
Following vein graft revision, ongoing clinical and colour
duplex surveillance is recommended as the risk of new
restenosis appears to be high. (Level 4; Grade C)
Following graft occlusion, intra-arterial thrombolysis may
be an option in patients without acute critical ischaemia
and a recent occlusion (<14 days) of a prosthetic or vein
bypass above the knee and in place for at least 1 year,
provided that there are no contraindications and that
lysis can be accomplished safely. Surgical revision with a
new graft using an autologous vein remains the preferred
salvage procedure for other types of graft occlusion.
(Level 2b; Grade C)
Failing or failed endovascular revascularisations can be
treated with similar efﬁcacy by endovascular or surgical
revision (Level 2b; Grade C). However, early repeated
endovascular interventions (<180 days) are associated
with a poor outcome. In these cases, a surgical alternative
may be preferable. (Level 4; Grade C)
Critical issues
• There is a need to study the best available treatment for
in-stent restenosis and after graft failure.
• A RCT is needed to evaluate the role of drug-eluting
stents for restenosis after angioplasty and for venous graft
stenosis.
5. Follow-up in speciﬁc contexts
5.1. Diabetic patients
A large proportion of CLI patients are diabetic59 and may
be challenging to manage. Expected clinical outcomes
are supposedly similar between surgical and endovascular
reconstruction,59 but as diabetic patients tend to present
with an advanced stage of peripheral vascular disease,
they may demonstrate reduced primary patency rates.59,78
However, with timely and repeated use of salvage re-
interventions, acceptable secondary patency and limb
salvage rates can be reached.78,79 Therefore, diabetic
patients are a subset likely to beneﬁt from close long-term
surveillance during follow-up.59
5.1.1. Patients with end-stage renal disease
The proportion of patients with both CLI and chronic
renal failure is increasing. But with an aggressive repeat
revascularisation approach, peri-operative mortality and
graft patency rates as well as expected 4-year survival
rates tend to approach those of patients with normal renal
function.80 The risk of amputation is however markedly
increased in dialysis patients.80––83 Major amputation despite
a patent graft occurs in 10% of patients with end-stage renal
disease,37,39 particularly when prosthetic graft material has
been used in non-ambulatory patients with extensive tissue
loss.37,38,80,82,84 In addition, secondary salvage procedures
after bypass occlusion have a poor prognosis in patients
with end-stage renal disease, and most will need a major
amputation within 1 year of graft failure.67
5.1.2. Elderly and functionally impaired patients
In elderly patients (80 years), quality of care for CLI
is not solely determined by the traditional measures of
patency and limb salvage but particularly by functional
outcomes. The most important predictor of preserved
ambulatory capacity is the patient state at presentation,
including mental state, pre-operative ambulatory capacity
and independent living status.40,85 General outlook after
open or endovascular revascularisation is fair for aged
ambulatory patients with CLI,86,87 even for below-the-
knee reconstructions.88 At 1 year, 88% of survivors are
ambulatory, 85% live at home, and 80% do both, whereas
at 5 years, 71% are still ambulatory, and 81% live
independently.40 Therefore, those who were ambulatory and
lived at home pre-operatively almost invariably continue
to do so. Those with poor ambulatory function or who
required assistance pre-operatively, however, are unlikely
to improve their status after revascularisation even if
technically successful.40,85,88 These ﬁndings question the
appropriateness of revascularisation in functionally impaired
and chronically ill patients.
Recommendations
Diabetic patients are likely to beneﬁt from close clinical
and colour duplex-scan surveillance as primary patency
rates are low and ankle-brachial pressure index may be
unreliable. (Level 2b; Grade C)
Patients with end-stage renal disease and patients who
are not ambulatory or are mentally incapacitated are
unlikely to proﬁt from any kind of continued limb salvage
efforts. This is particularly true if tissue loss is extensive
and no adequate autologous vein is available. (Level 2b;
Grade C)
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